Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
Bruker (BRKR) shares sold off after mixed fourth quarter 2025 results, as revenue slightly topped expectations while adjusted earnings per share missed forecasts and 2026 guidance pointed to relatively modest organic growth.
See our latest analysis for Bruker.
The latest results and 2026 guidance have reset expectations, and that shift is showing up in the chart, with a 1 day share price return of 2.67% decline, a 30 day share price return of 25.70% decline, and a 1 year total shareholder return of 26.68% decline. This indicates fading momentum as investors reassess Bruker’s growth outlook and risk profile despite recent product launches and acquisitions.
If Bruker’s earnings reset has you rethinking where growth could come from next, it may be worth scanning our 25 healthcare AI stocks as a starting list of potential ideas.
With the shares down sharply and trading at a reported intrinsic discount of about 28%, plus roughly 36% below the average analyst price target, is Bruker a reset story on sale, or is the market already discounting future growth?
Bruker’s most followed narrative pegs fair value at $54.43 per share versus the last close of $36.51, and the gap hinges on a detailed earnings and margin reset story.
The company’s pipeline of recent innovations (e.g., next-generation tims mass spectrometry, spatial biology, automated diagnostics) positions it to benefit from sustained investment in personalized medicine, genomics, and high-throughput scientific R&D, supporting both future revenue expansion and favorable product mix improvements.
For readers interested in what revenue trajectory and margin rebuild would need to occur to support that fair value, and how the future P/E is incorporated, the full narrative lays out the specific growth, profitability, and discount rate assumptions driving that $54.43 number.
Result: Fair Value of $54.43 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, you still need to weigh the risk that research funding stays soft and order momentum weakens further, which could pressure both revenue and margin expectations.
Find out about the key risks to this Bruker narrative.
If you look at the numbers and reach a different conclusion, or simply prefer to test your own assumptions, you can build a custom view in just a few minutes and then Do it your way.